Ionis announces positive data from GSK's Phase 2b clinical study of bepirovirsen
Retrieved on:
Tuesday, November 8, 2022
DC, Hepatitis B virus, The New England Journal of Medicine, Judgement, U.S. Securities and Exchange Commission, Ionis Pharmaceuticals, HBV, Patient, Association, Nas, Company, Blood, GSK, American Association for the Study of Liver Diseases, IONS, Knowledge, LD, American Association, Liver cancer, Immune system, RNA, Life, Arm, Disease, Conditional sentence, Hepatocyte, Drug development, COVID-19, Enzyme, Degenerative disease, ASO, View, Goal, Protein, Nasdaq, DNA, Limit inferior and limit superior, Liver failure, NA, Cirrhosis, Form 10-K, Annual report, Multimedia, Therapy, Safety, AASLD, Security (finance), CHB, HBsAg, Vaccine, Pharmaceutical industry, Poultry, Generic drug, Ionis
The study results were presented at the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting in Washington, DC.
Key Points:
- The study results were presented at the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting in Washington, DC.
- "Ionis is pleased with the results of the Phase 2b B-Clearstudy and to see bepirovirsen advance to Phase 3 clinical studies for the potential to offer a first-in-class therapy for people with CHB, including the possibility of functional cures.
- This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of Ionis' technologies, bepirovirsen and other products in development.
- In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our," and "us" refers to Ionis Pharmaceuticals and its subsidiaries.